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Enhanced non-vitreous cryopreservation of
immortalized and primary cells by ice-growth
inhibiting polymers†
Robert C. Deller,‡a,b Jeﬀrey E. Pessin,c,d Manu Vatish,e Daniel A. Mitchellf and
Matthew I. Gibson*a,f
Cell cryopreservation is an essential tool in modern biotechnology and medicine. The ability to freeze,
store and distribute materials underpins basic cell biology and enables storage of donor cells needed for
transplantation and regenerative medicine. However, many cell types do not survive freezing and the
current state-of-the-art involves the addition of signiﬁcant amounts of organic solvents as cryoprotec-
tants, which themselves can be cytotoxic, or simply interfere with assays. A key cause of cell death in
cryopreservation is ice recrystallization (growth), which primarily occurs during thawing. Here it is demon-
strated that the addition of ice recrystalization inhibiting polymers to solutions containing low (non vitrify-
ing) concentrations of DMSO enhance cell recovery rates by up to 75%. Cell functionality is also
demonstrated using a placental cell line, and enhanced cryopreservation of primary rat hepatocytes is
additionally shown. The crucial role of the polymers architecture (chain length) is shown, with shorter
polymers being more eﬀective than longer ones.
Introduction
The ability to store cells and tissues by cryopreservation is
crucial in biochemistry, cell biology, and clinical medicine.1,2
Current cryopreservation strategies require the addition of
large volumes (10–20 wt%) of membrane permeable organic
solvents (e.g. glycerol or DMSO) and often precise freezing
rates to promote either vitrification or dehydration and limit
intracellular ice formation (nucleation) and growth.3 These sol-
vents are cytotoxic in this concentration range at physiologi-
cally relevant temperatures and hence must be added/removed
rapidly to reduce cellular damage, which would perturb sub-
sequent assays/testing.4–6 With immortalized cells, reduced
cell counts can often (but not always) be overcome by simple
proliferation. This is typically not possible with primary cells
in vitro, necessitating donors, which are a limited resource.
Analysis of cryopreservation has identified that ice crystal
growth (recrystallization) during the thawing process is a
major cause of cell death (as is intracellular ice nucleation)
and is hence a valid target for enhanced cryopreservation.7
The most well-known ice recrystallization inhibitors (IRIs) are
antifreeze (glyco)proteins (AF(G)P)s (Fig. 1A) which can halt ice
growth at sub mg mL−1 concentrations.3,8–10 Carpenter et al.
have demonstrated that supplementing erythrocyte cryopreser-
vation solutions with closely related antifreeze proteins (AFPs)
can increase cell number post-thawing, but was limited by the
onset of dynamic ice shaping (DIS). DIS was shown to incite
mechanical damage that outweighed the benefits attained by
IRI activity.11 Other attempts to employ AF(G)Ps have met with
mixed results; Wang et al. reported that AF(G)P had a detri-
mental eﬀect on rat cardiac explant cryopreservation even at
concentrations as low as 10 μg mL−1 (ref. 12) and Koshimoto &
Mazur described how AFP and AF(G)P addition had an adverse
eﬀect on spermatozoa storage.13 However success has been
demonstrated with islet cells14 and oocytes.15 Understanding
the mechanisms and optimizing the application of AF(G)Ps is
also limited by their low availability from natural sources and
challenging synthesis, which only yields milligrams of
product.16 To address this, Gibson et al., have demonstrated
that biomimetic polymers can reproduce the most desirable
properties of AF(G)Ps and are readily synthesized, highly tune-
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able and produced on an industrial scale.17,18 In particular,
poly(vinyl alcohol) (PVA) has extremely potent IRI activity com-
parable to AF(G)Ps19–21 and is FDA approved for various
pharmaceutical, in vivo, and food applications (Fig. 1A).22 PVA
is also a potent antinucleating agent, which has been success-
fully used in the vitrification of organs.23,24 Other polymers
such a poly(vinyl pyrollidone) and hydroxyethyl starch have
been used as non-penetrative cryoprotectants but do not
possess IRI activity.1,17,25 Gibson et al. have shown that
addition of PVA (9 kDa) to red blood cells increases the yield of
cells post-thawing, and even enables solvent-free storage, by
inhibiting ice growth, rather than formation (nucleation).26–28
Whilst an interesting observation, red blood cells are anuclear
and do not proliferate, meaning any toxic eﬀects are less
pronounced.
Here, we investigate the use of PVA as an ice recrystalliza-
tion inhibitor to reduce cell damage during freezing of a range
of nucleated, immortalized cell types (A549, BeWo and FAO)
and primary rat hepatocytes, using minimal DMSO concen-
trations. Rapid (A549 and BeWo) and slow (FAO and Primary)
freezing methods are employed and the eﬀect of the polymer,
its architecture and the cell type are studied, demonstrating
this to be a simple, but eﬀective strategy.
Results and discussion
The chemical structure of the structurally simple, biomimetic,
ice recrystallization inhibiting (IRI) polymer, PVA, is shown
compared to native AF(G)P (Fig. 1A). Example ice wafers grown
with and without the PVA additive are also included (Fig. 1B),
demonstrating that within 30 minutes large (>200 μm) ice crys-
tals have grown in the absence of PVA, but addition of just
1 wt% (10 mg mL−1) of 9 kDa PVA completely halts ice crystal
growth (as we have previously reported17). This ability to halt
recrystallization (growth) is the primary mechanism of protec-
tion to be investigated here.
Three immortalized cell types were selected, along with
primary rat hepatocytes (vide infra) for use in this study. A549
cells (human lung adenocarcinoma) are routinely used in bio-
chemical studies as mimics of type II alveolar epithelial cells;29
BeWo cells (human choriocarcinoma) are placental derived
and show well-characterized responses to forskolin stimulation
enabling functionality as well as viability to be evaluated;30
FAO cells (rat hepatoma) provide a model for primary hepato-
cytes with additional use in pharmacokinetic and pharmacody-
namic studies.31,32 Cytotoxicity screening of 25 mg mL−1 PVA
with each immortalized cell line after 4 hours of exposure
(Fig. 1C) indicated there was no sign of cytotoxicity as expected
for this material22 even at the concentration applied which is
at least 10 fold higher than would be used in a cryopreserva-
tion context. PVA has been reported to undergo hydrogel for-
mation under cryogenic conditions but at significantly higher
concentrations (>10× fold) and molecular weights and was not
a property observed in this system.33
Typical cryopreservation conditions for these cell lines
would involve addition of ≈10 wt% DMSO in cell media
(although many laboratories use conditions they optimise indi-
vidually). To enable us to study the influence of the PVA addi-
tive, a range of trial cryopreservation tests were conducted (ESI
Fig. 1†) to find the DMSO concentration, which, under our
freezing conditions, yielded the greatest recovery. However it
must be highlighted that the complete removal of DMSO
results in zero recovery regardless of the inclusion of PVA or
not. Furthermore, changes in freezing/thawing rates will
obviously have an eﬀect (i.e. nucleation or vitrification), but
were outside of the scope of this particular study. Each cell
line was cultured to confluence and then added to cryovials
(1.8 mL) as 1 mL aliquots suspended in either phosphate
buﬀered saline (PBS) or complete medium with the pre-
determined amounts of DMSO and PVA. Post-freezing, cells
were thawed at 23 °C (air), to encourage ice recrystallization
and enable the impact of IRI activity to be measured. This is
also a more practical method, and representative of the storage
of larger volumes (e.g. organs) where thermal gradients exist
during thawing and rapid, homogeneous thawing is challen-
ging. Thawed cells (A549) were plated and incubated overnight
and cell metabolic activity (MTT) measured (Fig. 2).
The addition of just 1 mg mL−1 (0.1 wt%) of PVA to the
DMSO cryopreservation solution resulted in a 20% increase in
the cell (A549) metabolic activity (i.e. viability) post-thawing,
Fig. 1 PVA structure, IRI activity and cytotoxicity. (A) Structure of AF(G)P
and PVA; (B) micrographs of ice crystals annealed for 30 minutes at
−6 °C showing inhibitory eﬀect of PVA; (C) cytotoxicity testing of 25 mg
mL−1 PVA (9 kDa) after 4 hour incubation. Cell metabolic activity
measured by MTT (A549) and resazurin (BeWo and FAO) assays. Error
bars represent ± standard deviation from at least 3 repeats.
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providing a real benefit (p-value = 0.0331) (Fig. 2A). Interest-
ingly, addition of higher concentrations of PVA actually lead to
reduced cell viability. Cytotoxicity screening, at concentrations
far greater than used in cryopreservation, indicated that this is
not a toxic eﬀect of the polymer itself, so it is instead attribu-
ted to the unwanted eﬀect of DIS (the formation of needle-like
ice crystals) at higher PVA concentrations.20,34 This eﬀect was
more pronounced for the higher molecular weight, 31 kDa PVA,
which at just 1 mg mL−1 lead to a 75% decrease in metabolic
activity (p-value <0.0001). These data highlight that the architec-
ture and size of the polymer is crucial, as well as potent IRI
activity to achieve a successful cryopreservation enhancement
and a delicate balance must be struck. For example further
reductions in the molecular weight of PVA tends to a complete
loss of IRI activity.17,35 FITC (fluorescein isothiocyanate)
labelled PVA was also added to confluent A549 cells (Fig. 2B).
Following incubation and washing the total cell-associated fluo-
rescence was measured, revealing close to zero PVA has been
internalized or bound to the cell surface. This confirms our
hypothesis that PVA is a purely extracellular-functional additive,
and is particular useful for biomedical applications where all
additives need to be removed post-freeze/thaw rapidly.
Guided by the above results, cell-freezing using the FAO and
BeWo cell lines were conducted. With FAO cells (Fig. 3A) peak
enhancement was observed with 0.5 mg mL−1 of PVA (p-value =
0.0129), contrasted to 1 mg mL−1 for A549 which suggests
optimum conditions for each cell line need to be determined,
based on their own responses to cold-shock. As with A549 an
increase in viability of 20% was observed, which is significant
considering the minute quantities of PVA being applied. With
BeWo cells (Fig. 3B) the observed increase in metabolic activity
post-thaw was a remarkable 75% with 2 mg mL−1 PVA (9 kDa)
(p-value <0.0001). This obviously huge increase demonstrates
that under the correct conditions recrystallization inhibitors can
dramatically improve cryopreservation. As seen with FAO cells,
higher concentrations or addition of 31 kDa PVA (data not
Fig. 2 A549 Cryopreservation (rapid freezing) and FITC-PVA per-
meability. (A) Post freeze–thaw A549 cell metabolic activity with and
without PVA additives (MTT assay); (B) FITC-labelled PVA uptake into
A549 cells following 2 hours exposure at 37 °C). All data from at least 3
repeats and errors bars represent ± standard deviation. * represents p ≤
0.05 relative to DMSO only.
Fig. 3 FAO (slow freezing) and BeWo (rapid freezing) cryopreservation.
(A) FAO cell metabolic activity post-freeze–thaw as determined by resa-
zurin assay; (B) BeWo cell metabolic activity post-freeze–thaw as deter-
mined by resazurin assay; (C) β-hCG secretion (pg mL−1) due to
forskolin induced BeWo cell syncytialization, post cryopreservation. All
data from at least 3 repeats and errors bars represent ± standard devi-
ation. * represents p ≤ 0.05 relative to DMSO only.
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shown) lead to reductions in cell viability. These experiments
clearly show that IRI active polymers are a useful tool in cell
cryopreservation and can significantly enhance routine cell pres-
ervation without disruption to standard protocols, but that the
optimized concentration required for each cell type varies.
The above assays only probed cellular metabolic activity,
but we also wanted to probe if cellular function was aﬀected by
addition of the PVA. BeWo cells syncytialize and secrete β-hCG
(human pregnancy hormone) when exposed to forskolin
(50 μM) necessitating significant changes in gene expression.
A quantitative ELISA assay (Fig. 3C) revealed that β-hCG levels
were identical (or slightly higher, but not statistically signifi-
cant) in the PVA cryopreserved cells compared to DMSO only,
meaning that complex cellular function was unaﬀected by this
freezing method. It should be noted that β-hCG secretion does
not correlate linearly with cell number as cell-to-cell contact
(density) influences the rate and extent of syncytialization.
As a final test of this technique, primary cells were
employed as these are more sensitive and challenging to cryo-
preserve and are less straightforward to culture, hence maxi-
mizing their recovery is essential.1,36 Primary cells also tend to
be less tolerant to environmental perturbations ex vivo. Guided
by the positive results with the FAO cells, primary rat hepato-
cytes were harvested (sprague dawley) and prepared according
standard (percoll) protocols.37 No cytotoxicity was observed at
concentrations as high as 20 mg mL−1 PVA (Fig. 4A) (p-value =
0.0673 (120 minutes)), nor were there any morphological
changes. These cells were cryopreserved using a slow-freeze
methodology, then post cryopreservation, metabolic activity
was measured (resazurin) after plating and incubating cells
overnight. Compared to DMSO alone, addition of 1 mg mL−1
PVA gave >30% increase in cell recovery (Fig. 4B) (p-value
<0.001). As observed with the immortalized cells, higher con-
centrations of PVA (10 mg mL−1) led to reduced metabolic
activity (p-value <0.001) used as an indicator of cell recovery
associated with DIS, which is mitigated by limiting the concen-
tration of IRI agent applied. These results eﬀectively demon-
strate that IRI active compounds can indeed enhance cellular
cryopreservation, without requiring significant changes to
existing protocols making it a broadly applicable method
across a range of disciplines that employ cell culture.
Conclusions
Here the use of PVA to modulate ice crystal growth (IRI) during
cell freeze/thawing is described. Addition of just 1–3 mg mL−1
of PVA (9 kDa) to standard DMSO freezing protocols resulted
in an increase of 20–75% in total cell metabolic activity relative
to DMSO alone. This remarkable increase is being achieved
despite the weight fraction of the polymer additive being only
0.1–0.3 wt%. The mechanism of protection is linked to ice
growth inhibition, rather than nucleation inhibition (which is
crucial in vitrification). Functional assays on BeWo cells demon-
strated functionality retention by measurement of β-hCG
secretion, in addition to metabolic activity assays. Finally, freshly
isolated primary rat hepatocytes cells were also stored success-
fully using this approach with PVA giving a ≈35% increase in cell
metabolic activity relative to DMSO alone. This is particularly
important in the context of cryopreservation and distribution of
human tissue for transplantation. The mode of action of PVA
was shown to be purely extracellular, with no polymer permeat-
ing inside the cell, enabling its rapid removal post-thawing. As
PVA is commercially available to GMP standards, and already
has broad use in the pharmaceutical sciences and food industry,
it may find wide-ranging applicability in cryopreservation
scenarios.
Experimental section
Materials
All chemical and biochemical reagents were purchased from
Sigma-Aldrich Ltd (UK) or Life Technologies Ltd (UK) and
used without further purification except PVA. 9 kDa PVA
Fig. 4 Rat hepatocyte cytotoxicity and cryopreservation (slow freezing).
(A) Resazurin ﬂuorescence (cell metabolic activity assay) over 2 hours in
rat hepatocytes with and without of 20 mg mL−1 PVA; (B) cell metabolic
activity (%) of cryopreserved rat hepatocytes (1 × 106 cells per mL) each
plated overnight, relative to 10% (v/v) DMSO preservation alone as
judged by the resazurin assay after 6 hours. Freezing in complete
medium alone gave 0% cell recovery; all data from at least 3 repeats and
errors bars represent ± standard deviation. * represents p ≤ 0.05 relative
to DMSO only.
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(average Mw 9000–10 000, 80% hydrolysed) and 31 kDa PVA
(average Mw 31 000–50 000, 98–99% hydrolysed) were purified
further by dialysis (4 L H2O with at least 5 changes) against
1000 MWCO membranes (Spectrum Laboratories Inc., CA,
USA) to remove any small molecule weight contaminants, prior
to freeze drying to yield a lyophilized solid for further use.
Each immortalised cell line used was derived from stocks orig-
inally obtained from the American Type Culture Collection
(ATCC) (VA, USA) and propagated using standard cell culture
practices prior to use.
Ice recrystallization inhibition assay
Ice recrystallization inhibition (IRI) was investigated using a
modified “splat” assay according to previously published
protocols.10,25 In brief, a 10 μL droplet is expelled onto a no. 0
thickness coverslip placed upon a pre-cooled (CO2(s)) aluminium
(below a minimum of −40 °C) plate creating a polycrystalline
wafer containing ice crystals (<10 μm in diameter). The coverslip
is immediately transferred to a N2(l) cooled linkam BCS196 cryo-
stage (Linkam Scientific Instruments Ltd, UK.) at −6 °C for
30 minutes prior to imaging using an Olympus CX41 microscope
equipped with a UIS-2 10×/0.25/N/–/FN22 lens, cross polarizers
(Olympus Ltd, Southend on sea, UK) and a Canon EOS 500D
SLR digital camera (Canon (UK) Ltd, Surrey, UK). The sizes of
the ten largest crystals were measured using the freely available
image-processing software ImageJ38 and the mean largest
grain size expressed as a percentage of a PBS control.
Cytotoxicity assessment of PVA to A549, BeWo, FAO and
primary rat hepatocytes
Purified PVA (9 kDa) was dissolved in PBS at 25 mg mL−1 and
incubated with A549, BeWo and FAO cells for 4 hours in a
37 °C/5% CO2(g) humidified incubator. Immediately afterwards
cells were washed with PBS and cell viability measured by stan-
dard MTT39(A549) and resazurin40 (BeWo and FAO) assays.
Metabolic activity was expressed as a % against untreated con-
trols (in the absence of DMSO) with the mean values of at least
3 replicates reported. Primary rat hepatocytes (8 × 105 cells)
were plated in triplicate onto 60 mm ∅ collagen (type I) coated
plates (BD Biosciences, CA, USA) for 3 hours in complete
(DMEM) medium at 37 °C. Afterwards cells were washed twice
with PBS to remove any non-adherent cells and debris and
then replaced with complete medium for 36 hours at which
point the inherent metabolic activity was assessed by the non-
destructive resazurin assay (enabling measurements at mul-
tiple time points). Afterwards, these primary rat hepatocytes
were treated with 20 mg mL−1 PVA in complete medium for
4 hours, washed and then viability assessed by the resazurin
assay. The total fluorescence before and after PVA addition was
taken at 20 minute intervals for a period of 2 hours allowing
the eﬀect of PVA to be investigated with the mean values of at
least 3 replicates reported.
Cryopreservation of A549 and BeWo cells
A549 and BeWo cells were subjected to a rapid freezing proto-
col. Confluent cells (RPMI containing 10% (v/v) FBS plus
100 U per mL Penicillin, 100 μg per mL streptomycin) were
trypsinised, washed and resuspended in PBS containing the
appropriate amount of DMSO and desired PVA (in PBS) to a
volume of 1 mL in 1.8 mL cryovials (between 1 × 105–1 × 106
cells per mL). Cells without PVA were given an equivalent
volume of PBS and DMSO. Preparations were mixed by inver-
sion to ensure homogeneity prior to immersion in a (−78 °C)
IPA/CO2(s) slurry for 60 seconds and were enclosed in CO2(s) for
a period of 20 minutes. Cells were thawed slowly at 23 °C in air
to maximize potential ice recrystallization. Once thawed, cells
were plated as a monolayer in complete medium in 48/96 well
plates and incubated overnight in a 37 °C/5% CO2(g) humidi-
fied incubator prior to viability and functionality assays.
Syncytialization and functionality assessment of BeWo cells
After cryopreservation BeWo cells were plated as a monolayer
in a 48-well plate overnight to enable adhesion prior to the
addition of 50 µM forskolin (10 mM stock in DMSO) in com-
plete medium for 72 hours enabling syncytialization. The pro-
duction of β-HCG was investigated using a β-HCG ELISA kit
specific for detecting β-HCG present within cell culture
medium with the mean values of at least 3 replicates reported.
Cryopreservation of FAO cells and primary rat hepatocytes
FAO and primary rat hepatocytes were subjected to a slow
freezing protocol. Confluent or freshly isolated cells were tryp-
sinised (as appropriate), washed and resuspended in medium
(RPMI for FAO and DMEM for primary hepatocytes) containing
10% (v/v) FBS plus 100 U per mL penicillin, 100 μg per mL
streptomycin with the appropriate amount of DMSO and
desired PVA (in complete medium) to a volume of 1 mL in
1.8 mL cryovials. FAO cells were cryopreserved at a concen-
tration between 1 × 105–1 × 106 cells per mL and primary rat
hepatocytes at 1 × 106 cells per mL. Cells without PVA were
given an equivalent volume of medium. Cells were then cooled
to 4 °C in a Nalgene “Mr. Frosty™” containing IPA over a
period of 120 minutes. Cooled cells were transferred to −80 °C
for between 24–72 hours and finally placed into vapour phase
N2(l) (−196 °C) overnight. Cells were thawed slowly at 23 °C in
air to maximize potential ice recrystallization. Once thawed,
FAO cells were plated as a monolayer in complete medium in
48/96 well plates and incubated overnight in a 37 °C/5% CO2(g)
humidified incubator prior to viability and functionality
assays. Thawed primary rat hepatocytes were plated as a mono-
layer on 60 mm ∅ collagen (type I) coated plates and incubated
for 3 hours. Primary rat hepatocytes were then washed twice
with PBS to remove any non-adherent cells and debris and
then replaced with complete medium and incubated overnight
in a 37 °C/5% CO2(g) humidified incubator prior to viability
and functionality assays.
Data analysis
All statistics and calculations for (%) cell recovery and (%)
mean largest grain size were determined using Microsoft Excel
2008 for Mac. Significance determination for cryopreservation
data used a two-tailed homoscedastic Student’s t-test with a
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95% confidence interval (P-value ≤0.05) comparing the value
of stated interest with the relevant control.
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